US-based laboratory diagnostics provider med fusion has introduced a new plasma-based epidermal growth factor receptor (EGFR) liquid biopsy service, which is integrated with Swiss healthcare firm Roche’s cobas EGFR mutation test v2.

Approved by the US Food and Drug Administration (FDA), the cobas mutation test is designed to detect 42 mutations in the EGFR gene.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The test enables physicians to decide the eligibility of non-small cell lung cancer (NSCLC) patients for treatment with an EGFR tyrosine kinase inhibitor (TKI).

med fusion chief executive officer Jon Hart said: “med fusion’s ultimate goal is to improve patient care by providing responsible precision medicine solutions.

“Expanding our menu to include the EGFR liquid biopsy test helps us accomplish our goal by providing physicians with a reliable, non-invasive test to determine EGFR mutation status and related treatment options for their NSCLC patients when tissue biopsies are not available.”

The firm’s new service complements its current LungSEQ and 50SEQ Plus FISH decision support tools.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"The non-invasive test uses a blood sample to perform EGFR mutation testing when it is not possible to obtain tissue biopsies or in the case of insufficient availability of specimen."

The non-invasive test uses a blood sample to perform EGFR mutation testing when it is not possible to obtain tissue biopsies or in the case of insufficient availability of specimen.

Roche Diagnostics president and chief executive officer Jack Phillips said: “We’re honoured that med fusion is using Roche’s test as the basis for their EGFR liquid biopsy service.

“This is a service that will benefit their network of physicians and the lung cancer patients they serve, and we are proud to be part of it.”

In June 2012, Roche established a strategic partnership with med fusion, recognising it as a Roche Molecular Centre of Excellence (MCOE).

med fusion provides new and advanced molecular diagnostics to physicians and patients.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact